DK3234107T3 - B-celler til in vivo-levering af terapeutiske midler - Google Patents

B-celler til in vivo-levering af terapeutiske midler Download PDF

Info

Publication number
DK3234107T3
DK3234107T3 DK15871244.8T DK15871244T DK3234107T3 DK 3234107 T3 DK3234107 T3 DK 3234107T3 DK 15871244 T DK15871244 T DK 15871244T DK 3234107 T3 DK3234107 T3 DK 3234107T3
Authority
DK
Denmark
Prior art keywords
cells
therapeutic agents
vivo delivery
vivo
delivery
Prior art date
Application number
DK15871244.8T
Other languages
English (en)
Inventor
Matthew Rein Scholz
Eric J Herbig
Mei Xu
Laat Rian De
Original Assignee
Immusoft Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immusoft Corp filed Critical Immusoft Corp
Application granted granted Critical
Publication of DK3234107T3 publication Critical patent/DK3234107T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4612—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/056—Immunostimulating oligonucleotides, e.g. CpG
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/231—Interleukin-10 (IL-10)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK15871244.8T 2014-12-19 2015-12-18 B-celler til in vivo-levering af terapeutiske midler DK3234107T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462094794P 2014-12-19 2014-12-19
US201562110063P 2015-01-30 2015-01-30
PCT/US2015/066908 WO2016100932A1 (en) 2014-12-19 2015-12-18 B cells for in vivo delivery of therapeutic agents

Publications (1)

Publication Number Publication Date
DK3234107T3 true DK3234107T3 (da) 2022-10-17

Family

ID=56127743

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15871244.8T DK3234107T3 (da) 2014-12-19 2015-12-18 B-celler til in vivo-levering af terapeutiske midler

Country Status (8)

Country Link
US (2) US20180002664A1 (da)
EP (2) EP4177336A1 (da)
CA (1) CA2971430A1 (da)
DK (1) DK3234107T3 (da)
ES (1) ES2929570T3 (da)
HK (1) HK1245834A1 (da)
PL (1) PL3234107T3 (da)
WO (1) WO2016100932A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6392315B2 (ja) 2013-03-14 2018-09-19 イミュソフト コーポレーション インビトロでのメモリーｂ細胞分化方法およびｖｓｖ−ｇ偽型ウイルスベクターを用いる形質導入方法
WO2016161446A1 (en) * 2015-04-03 2016-10-06 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
AU2017322733B2 (en) * 2016-09-12 2024-05-09 Regents Of The University Of Minnesota Genome edited primary B cell and methods of making and using
CN110494565A (zh) * 2016-12-02 2019-11-22 朱诺治疗学股份有限公司 工程化b细胞及相关组合物和方法
WO2018140573A1 (en) * 2017-01-26 2018-08-02 Sangamo Therapeutics, Inc. B-cell engineering
WO2018201071A1 (en) * 2017-04-27 2018-11-01 Immusoft Corporation B cells for in vivo delivery of therapeutic agents and dosages thereof
AU2019233929A1 (en) * 2018-03-16 2020-09-24 Immusoft Corporation B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strength
US11913023B2 (en) 2020-03-31 2024-02-27 Walking Fish Therapeutics, Inc. Modified B cells and methods of use thereof
KR20230091865A (ko) * 2020-09-02 2023-06-23 워킹 피쉬 테라퓨틱스 인코포레이티드 변형 b 세포 및 이의 사용 방법
WO2022094284A1 (en) * 2020-10-30 2022-05-05 Immusoft Corporation Methods of administering genetically modified b cells for in vivo delivery of therapeutic agents
WO2024040201A1 (en) * 2022-08-19 2024-02-22 Celdara Medical Llc Improved method and system for cell therapy

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
JPH0276820A (ja) * 1988-06-15 1990-03-16 Ajinomoto Co Inc 骨髄移植療法支持剤
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
US5057423A (en) 1987-12-18 1991-10-15 University Of Pittsburgh Method for the preparation of pure LAK-active lymphocytes
US5124259A (en) 1989-08-23 1992-06-23 Mitsui Toatsu Chemicals, Inc. Method for electroporation
US5297983A (en) 1991-07-15 1994-03-29 Albert Handtmann Maschinenfabrik Gmbh & Co., Kg Process and device for separating and placing a gut caterpillar on a filling tube
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
WO1995004521A1 (en) 1993-08-10 1995-02-16 W.L. Gore & Associates, Inc. Cell encapsulating device
DE69533544T2 (de) 1994-01-11 2006-02-23 Dyax Corp., Cambridge Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
US5651981A (en) 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
US5626561A (en) 1995-06-07 1997-05-06 Gore Hybrid Technologies, Inc. Implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein
DE69630266T2 (de) 1995-06-07 2004-09-09 W.L. Gore & Associates, Inc., Newark Implantierbare aufnahmevorrichtung für ein therapeutisches gerät
WO1997010807A1 (en) 1995-09-22 1997-03-27 Gore Hybrid Technologies, Inc. Improved cell encapsulation device
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7381701B2 (en) 2001-02-15 2008-06-03 The Borad Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
KR100955973B1 (ko) 2001-02-15 2010-05-04 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 세포 사멸을 조절하는 세포독성인자
US7301010B2 (en) 2001-02-15 2007-11-27 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating HIV infection with cupredoxin and cytochrome c
US7491394B2 (en) 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
US7556810B2 (en) 2005-07-19 2009-07-07 The Board Of Trustees Of The University Of Ilinois Compositions and methods to control angiogenesis with cupredoxins
US7338766B2 (en) 2001-02-15 2008-03-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating malaria with cupredoxin and cytochrome
JP4191998B2 (ja) 2001-02-19 2008-12-03 ポーラ化成工業株式会社 エレクトロポレーション用の組成物
CA2594356C (en) 2005-01-05 2018-07-17 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
GB0504767D0 (en) 2005-03-08 2005-04-13 Ares Trading Sa Lipocalin protein
ES2425571T3 (es) * 2005-11-17 2013-10-16 Biogen Idec Ma Inc. Ensayos de agregación plaquetaria
ES2444465T5 (es) * 2005-12-09 2023-11-30 Academisch Medisch Centrum Bij De Univ Van Amsterdam Medios y procedimientos para influenciar la estabilidad de las células productoras de anticuerpos
US7799555B2 (en) 2006-02-10 2010-09-21 Bio-Rad Laboratories, Inc. Apparatus for high-throughput electroporation
EP1829895A1 (en) 2006-03-03 2007-09-05 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
US8551780B2 (en) 2008-02-01 2013-10-08 H. Lee Moffitt Cancer Center & Research Institute, Inc. Electroporation buffer composition and method of use
EP2358868B1 (en) 2008-11-21 2014-11-12 California Institute of Technology In vitro human b lymphopoiesis culture system
JP5873807B2 (ja) 2010-01-08 2016-03-01 イミュソフト コーポレーション Ｂ細胞を形質導入するためのベクターおよび方法
JP5578338B2 (ja) 2010-03-15 2014-08-27 国立大学法人山口大学 哺乳動物細胞への遺伝子導入効率の向上剤
EP2601289B1 (en) * 2010-08-04 2017-07-12 Cellular Dynamics International, Inc. Reprogramming immortalized b cells
JP6148679B2 (ja) * 2011-12-14 2017-06-14 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド 中枢神経系の損傷の治療のためのヒト単球亜集団
JP6392315B2 (ja) 2013-03-14 2018-09-19 イミュソフト コーポレーション インビトロでのメモリーｂ細胞分化方法およびｖｓｖ−ｇ偽型ウイルスベクターを用いる形質導入方法

Also Published As

Publication number Publication date
EP3234107B1 (en) 2022-09-14
PL3234107T3 (pl) 2023-01-16
ES2929570T3 (es) 2022-11-30
EP3234107A1 (en) 2017-10-25
WO2016100932A1 (en) 2016-06-23
HK1245834A1 (zh) 2018-08-31
CA2971430A1 (en) 2016-06-23
EP4177336A1 (en) 2023-05-10
US20180002664A1 (en) 2018-01-04
EP3234107A4 (en) 2018-07-04
US20230081163A1 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
DK3234107T3 (da) B-celler til in vivo-levering af terapeutiske midler
BR112018009951A2 (pt) fármaco oftálmico
DK3235465T3 (da) Implantat
BR112016030368A2 (pt) composição oftálmica
DK3356313T3 (da) 2-perfluorhexyloktan til oftalmisk indgivelse
DK3204876T3 (da) Lægemiddelafgivelsesindretning
DK3590543T3 (da) Medicinsk forbinding
DK3148625T3 (da) Opklappelig kateterpakning
DK3134095T3 (da) Forbedrede fremgangsmåder til fremstilling af adoptive celleterapier
DK3692857T3 (da) Indretning til levering af hudplejesammensætning
DK3107563T3 (da) Glycomålrettede terapeutiske midler
DK3162402T3 (da) Næsespraydyse til anvendelse i medicinsk sprøjte
BR112016026879A2 (pt) Composição farmacêutica líquida
DK3197472T3 (da) Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri
DK3223829T3 (da) Behandling af sygdomme associeret med hepatisk stellat-celleaktivering under anvendelse af ammoniak-sænkende terapier
MA39483A (fr) Agents thérapeutiques cibles
DK3494962T3 (da) Flydende inhalationsformulering omfattende RPL554
DK3882250T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser
DK3102254T3 (da) Injektionsindretning
DK3094322T3 (da) Administration af tasimelteon i fastende tilstand
DK3171700T3 (da) Infusionsanlæg
DK3456330T3 (da) Cortexolon-17alpha-valerat til anvendelse ved behandling af tumorer
DK3166911T3 (da) Inkorporering af biologiske midler i gødning
DK3391902T3 (da) Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati
DK3363428T3 (da) Perfusionsdoseringsform